Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study November 7, 2026 Genitourinary Cancer
Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer November 7, 2026 Genitourinary Cancer
Docetaxel, Estramustine, and Exisulind in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy November 7, 2026 Genitourinary Cancer
Androgen Suppression Plus Radiation Therapy in Treating Patients With Prostate Cancer November 7, 2026 Genitourinary Cancer
Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy November 7, 2026 Genitourinary Cancer
Nitrocamptothecin in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy November 7, 2026 Genitourinary Cancer
Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer November 7, 2026 Genitourinary Cancer
Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study November 7, 2026 Genitourinary Cancer
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer November 7, 2026 Genitourinary Cancer